Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
NCT06414096
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Hypothesis: The investigators hypothesize that pulsatile FSH intravenous administration to women with obesity will correct the Reprometabolic Syndrome (RMS) luteal deficiency phenotype. Specific Aim: To test the hypothesis that pulsatile IV administration of FSH will rescue the impaired folliculogenesis and relative hypogonadotropic hypogonadism, characteristic of obesity. This study will also try to rescue the diminished ovarian reserve phenotype in the same fashion.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Infertility
- Obesity
- Diminished Ovarian Reserve (DOR)
- Diminished Ovarian Reserve
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 19 to 37 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Anschutz Medical Campus · Aurora, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.